were among the worst-performing health-related stocks Friday, plummeting 45% after the biotech company halted its trial for a kidney cancer drug.
Antigenics said the trial was halted based on the number of events -- defined as recurrence of disease or death of a patient prior to recurrence -- reported by the study's investigators. An independent review panel found that the number of events that occurred were significantly lower than reported by the investigators. The independent panel determined that the required number of events to conduct an analysis of the drug's primary endpoint, recurrence-free survival, wasn't met.
"We believe that further work is necessary to properly interpret these results," the company said. Antigenics said that it plans to analyze the data, which will take about four to six weeks.
In the meantime, the company has decided to suspend part two of the kidney cancer trial until it examines data from part one. Antigenics also said it would immediately implement a restructuring plan aimed at reducing cash burn. Shares were trading down $2.28 to $2.83.
tumbled 27% after the company and its partner,
, modified the dosage rate of valopicitabine in its hepatitis C clinical trial. The company lowered the dosage rate from 800 milligrams per day to 200 milligrams or 400 milligrams per day because of dose-related gastrointestinal side effects that were observed in certain patients who were receiving 800 milligrams.
"While these modifications will delay the valopicitabine development program, the primary purpose of phase II studies is to identify the optimal dosing regimen with respect to efficacy and safety," Idenix said. Shares were trading down $5.55 to $14.70.
rose 4% after Standard & Poor's said it plans to add the health services company to its S&P SmallCap 600 index after the close of trading on March 30. Matria Healthcare will replace
( HUG), which is being acquired by
. Matria shares were trading up $1.54 to $38.09.
rose 2% after the drugmaker priced 9 million shares of stock at $13 apiece. The company also agreed to sell $150 million of 2.5% subordinated convertible notes due 2013. BioMarin expects to close the transactions on or about March 29. The company plans to use proceeds from the offerings for the commercialization of its products, clinical trials and for working capital and other general needs. Shares were trading up 36 cents to $13.49.
jumped 13% after the biotechnology company expanded its relationship with
. The expanded agreement, which Senomyx called co-exclusive, now includes the commercialization of flavors and flavor enhancers in the pet food category. The previous agreement called for the discovery and commercialization of flavors in the dehydrated and culinary food, frozen food, and wet soup product categories. "We are extremely pleased to expand our agreement with Nestle into a large, new category," Senomyx said. Shares were trading up $1.84 to $16.25.
Other health care volume movers included
, up 23 cents to $3.72;
( CEPH), down $10.02 to $63.29;
, down 17 cents to $2.06;
, down 28 cents to $25.88;
( KG), down 24 cents to $17.12;
, up 5 cents to $25.55;
, up 25 cents to $23.72;
, up 19 cents to $7.47;
, up 17 cents to $13.84;
Johnson & Johnson
, down 32 cents to $60.49;
, up 42 cents to $73.22;
, down 9 cents to $36.11; and
( SGP), down 8 cents to $19.18.